1stOncology™: Cancer Intelligence Service – Page 13265 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Menarini Silicon Biosystems to Host ESMO Symposium on Clinical Importance of Circulating Tumor Cells

On September 23, 2019 Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, reported that it will host a symposium on the importance of liquid biopsy and circulating tumor cells (CTCs) in advancing precision medicine for patients with metastatic breast and prostate cancer (Press release, Menarini, SEP 23, 2019, View Source [SID1234539722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The pro+gram will take place at the 2019 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress and will feature some of the world’s leading clinical researchers in the field of liquid biopsy and CTCs. They will present summaries of available data supporting the clinical impact of prognostic value of CTCs in both early and advanced breast cancer, as well as in advanced prostate cancer. The researchers will also discuss potential clinical applications for liquid biopsy technologies and provide recommendations for using CTC enumeration to manage patients.

"Liquid biopsy plays an increasingly important role in bringing personalized medicine to patients with metastatic breast and prostate cancer," said symposium co-chair Wolfgang Janni, MD, University of Ulm, Germany. "The goal of this symposium is to define the role of CTCs and other blood-based markers in helping physicians better understand cancer evolution and progression. This is the future of precision medicine."

In addition to Dr. Janni, the distinguished presenters include co-chair Massimo Cristofanilli, MD, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; as well as faculty members Jean-Yves Pierga, MD, PhD, Institut Curie & Universite Paris Descartes, France, and Johann De Bono, MD, PhD, The Institute of Cancer Research and Royal Marsden, London, UK.

"The liquid biopsy field has grown tremendously in the past 15 years, thanks to the initial fundamental demonstration of the ability to detect circulating tumor cells in the blood of cancer patients and the continual improvements in CTC detection and characterization technology," said Dr. Cristofanilli. "Attendees can expect to get a comprehensive overview of state-of-the-art technology for CTC analysis. In addition, they will take part in discussions with the faculty about the future of this field and how we can move toward liquid biopsy as a standard of care for patients with advanced disease."

New Clinical Perspectives of CTCs in the Era of Precision Medicine will take place 28 September 2019, 18:30-20:00 in Santander Auditorium, Hall 3, Fira Gran Via, Barcelona Spain. The presentations are:

A single baseline CTC count for staging of metastatic Breast Cancer: Beyond anatomical description – M Cristofanilli
Prognostic and predictive value of CTC count in the management of HR+ Metastatic Breast Cancer – JY Pierga
Prognostic role of CTC detection in HR+ Early Breast Cancer – W Janni
CTC count and single cells evaluation in metastatic Prostate Cancer – J De Bono
The program will conclude with a 30-minute roundtable discussion between the faculty and audience members to discuss the current value of CTC enumeration for patient management and its potential future impact on clinical practice.

To learn more, ESMO (Free ESMO Whitepaper) attendees can visit Menarini Silicon Biosystems at Booth #311.

ESMO is the leading professional organization for medical oncology in Europe. The 2019 ESMO (Free ESMO Whitepaper) Congress will take place 27 September – 1 October, 2019, Barcelona, Spain.

Precision Optics Corporation Schedules Fourth Quarter and Fiscal Year 2019 Conference Call for Thursday, September 26, 2019

On September 23, 2019 Precision Optics Corporation, Inc. (OTCQB: PEYE) (the "Company") reported that it has scheduled a conference call to discuss fourth quarter and fiscal 2019 financial results on Thursday, September 26, 2019 at 5:00pm ET (Press release, Precision Optics, SEP 23, 2019, View Source [SID1234539721]).

The Company intends to release its financial results and to file its 10-K after the close of the market on September 26, 2019 followed by the conference call.

Conference Call Details

Date and Time: Thursday, September 26, 2019 at 5:00pm ET

Call-in Information: Interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789.

Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available at View Source

Replay: A teleconference replay of the call will be available until October 3, 2019 at (877) 344-7529 or (412) 317-0088, confirmation #10135010. A webcast replay will be available at View Source

Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference

On September 23, 2019 Nektar Therapeutics (Nasdaq: NKTR) reported that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02 study will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper), which is being held from September 25 to September 28, 2019, at the Espace Grand Arche de la Defense in Paris, France (Press release, Nektar Therapeutics, SEP 23, 2019, View Source [SID1234539720]). The PIVOT-02 study is evaluating bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in a range of advanced and/or metastatic solid tumor settings.

Poster Presentation:

Abstract #A001: "Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study", Tolaney, S., et al.

Session Date and Time: Thursday, September 26th from 1:00 p.m. – 3:00 p.m. and 6:30 p.m. – 8:00 p.m. Central European Time

Company to Host Webcast Conference Call at CRI-CIMT-EATI-AACR:
The company will host a webcast conference call with Dr. Sara M. Tolaney, MPH, Associate Director of the Susan F. Smith Center for Women’s Cancers and Assistant Professor of Medicine at Harvard Medical School and company management on Thursday, September 26th at 8:30 a.m. Eastern time during the CRI-CIMT-EATI-AACR conference following presentation of data. The webcast conference call will be accessible from the Investor Events page of Nektar’s website at View Source

Arcus Biosciences to Present Updated Data from the Phase 1 Safety Dose-Escalation Portion of the AB928 Combination Trials at the European Society for Medical Oncology (ESMO) Meeting

On September 23, 2019 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, reported that the Company will be presenting updated data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual antagonist of adenosine receptors A2aR and A2bR, in a poster display session at the 2019 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting taking place in Barcelona, Spain from September 27-October 1, 2019 (Press release, Arcus Biosciences, SEP 23, 2019, View Source [SID1234539719]).

Poster presentation details

Title: Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presentation Number: 1206P
Session Name: Poster Display Session
Date and Time: Monday, September 30, 12:00 p.m. – 1:00 p.m. Central European Summer Time (CEST)
Location: Poster Area (Hall 4), Fira Gran Via, Barcelona, Spain

A copy of the poster will be available on the "Publications" section of the Arcus website at www.arcusbio.com.

About AB928

AB928 is a dual antagonist of adenosine receptors A2aR and A2bR designed to block adenosine-mediated impairment of intra-tumoral immune cells, mainly lymphocytes (CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages). Developed specifically for the oncology setting, AB928 achieves high penetration of tumor tissue, robust potency in the presence of high adenosine concentrations, and minimal shift in potency from non-specific protein binding. Among agents in the clinic, AB928 is the only antagonist of A2bR, found on both myeloid cells and cancer cells. AB928 thereby uniquely blocks adenosine’s immunosuppressive and cancer cell-intrinsic effects in the tumor microenvironment. AB928 has demonstrated a favorable safety profile with a variety of combination regimens and exhibits pharmacokinetics / pharmacodynamics consistent with once-daily dosing. AB928 is currently in several ongoing Phase 1/1b expansion trials across multiple indications.

About AB122

AB122 is a fully human IgG4 antibody that potently and selectively blocks PD-1. The biochemical, biological and preclinical properties of AB122 have been shown to be similar to those of marketed anti-PD-1 antibodies. The Company is evaluating AB122 both as monotherapy and in combination as a core component for the Company’s intra-portfolio combinations. AB122 is progressing into a Phase 1b biomarker-selected trial across advanced solid tumors in collaboration with Strata Oncology utilizing Strata’s precision drug development platform and proprietary biomarkers. AB122 is also in Phase 1/1b expansion trials in combination with AB928, a dual antagonist of adenosine receptors A2aR and A2bR, in combination with AB154, its anti-TIGIT antibody, and in combination with AB680, its small-molecule CD73 inhibitor, plus chemotherapy.

Bioasis Announces Proposed Private Placement

On September 23, 2019 BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, reported that it intends to complete a brokered private placement financing (the "Offering") of units (the "Units") for gross proceeds of approximately US$4 million (Press release, biOasis, SEP 23, 2019, View Source [SID1234539718]).

Each Unit will consist of one common share of the company (a "Common Share") and one warrant to purchase one Common Share (a "Warrant") offered at CA$0.225, a 20% discount to the volume weighted average price per share of the company’s common shares on the TSXV over the 20 trading day period ending on September 20, 2019. Each Warrant will have a five year term and an exercise price equal to 120% of the Offering Price.

Boustead Securities, LLC are acting as the placement agent for U.S. investors participating in the Offering on a "best efforts" basis. The Agents will be paid a cash commission equal to 8% of the gross proceeds from the Offering and will also be issued broker warrants to purchase that number of Common Shares equal to 8% of the total number of Units sold in the Offering at a price equal to the Offering Price for a period of three years from the closing date of the Offering.

An initial closing of the Offering is expected to occur on or before September 27, 2019 and is subject to the satisfaction of waiver of certain conditions, including the delivery of definitive subscription agreements and TSX Venture Exchange approval. All the securities issued pursuant to the Offering will be subject to a hold period in Canada expiring four months and a day after the closing date and will be restricted securities for the purposes of United States securities laws.

The company intends to use the net proceeds from the Offering for manufacturing, IND enabling studies, legal expenses (including for patent and other intellectual property work) and for general working capital purposes.

"This financing will provide additional support to Bioasis as we progress xB3-001 as a treatment for HER2+ breast cancer and brain metastases. It follows the positive response we received from the FDA to our recent pre-IND submission and recognizes the strength of the company’s intellectual property covering xB3-001," said executive chair Deborah Rathjen, Ph.D.

"We believe that xB3-001, an xB3-Herceptin construct, may be an effective treatment for HER2+ brain metastases with the potential for accelerated approval," Dr. Rathjen continued. "Herceptin continues to be the backbone of treatment of HER2+ breast cancer despite its lack of brain penetrance. In preclinical animal models xB3-001 has demonstrated a 10-fold increase in brain penetrance and efficacy in the treatment of HER2+ brain tumors."